Cargando…
An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer
Although colorectal cancer is increasingly being diagnosed in older patients, their number is largely underrepresented in phase II or III clinical trials. Consequently, guidelines and the SIOG recommendations are not sufficiently clear regarding the treatment of these patients, particularly when che...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739901/ https://www.ncbi.nlm.nih.gov/pubmed/36498683 http://dx.doi.org/10.3390/jcm11237108 |
_version_ | 1784847924089323520 |
---|---|
author | Rosati, Gerardo Montrone, Michele Pacilio, Carmen Colombo, Alfredo Cicero, Giuseppe Paragliola, Fernando Vaia, Angelo Annunziata, Luigi Bilancia, Domenico |
author_facet | Rosati, Gerardo Montrone, Michele Pacilio, Carmen Colombo, Alfredo Cicero, Giuseppe Paragliola, Fernando Vaia, Angelo Annunziata, Luigi Bilancia, Domenico |
author_sort | Rosati, Gerardo |
collection | PubMed |
description | Although colorectal cancer is increasingly being diagnosed in older patients, their number is largely underrepresented in phase II or III clinical trials. Consequently, guidelines and the SIOG recommendations are not sufficiently clear regarding the treatment of these patients, particularly when chemotherapy is combined with monoclonal antibodies (bevacizumab, cetuximab, and panitumumab). Targeted therapy based on the use of anti-epidermal growth factor receptors (EGFRs) is conditioned by the potential for increased toxicity, making it more difficult to treat an older, rat sarcoma virus (RAS) and B rapidly accelerated fibrosarcoma (BRAF) wild-type patient. In light of a more detailed characterization of the older population, modernly differentiable between fit, vulnerable, or frail patients on the basis of the comprehensive geriatric assessment, and of the analysis of more recent studies, this review fully collects data from the literature, differentiating the results on functional status patients. |
format | Online Article Text |
id | pubmed-9739901 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97399012022-12-11 An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer Rosati, Gerardo Montrone, Michele Pacilio, Carmen Colombo, Alfredo Cicero, Giuseppe Paragliola, Fernando Vaia, Angelo Annunziata, Luigi Bilancia, Domenico J Clin Med Review Although colorectal cancer is increasingly being diagnosed in older patients, their number is largely underrepresented in phase II or III clinical trials. Consequently, guidelines and the SIOG recommendations are not sufficiently clear regarding the treatment of these patients, particularly when chemotherapy is combined with monoclonal antibodies (bevacizumab, cetuximab, and panitumumab). Targeted therapy based on the use of anti-epidermal growth factor receptors (EGFRs) is conditioned by the potential for increased toxicity, making it more difficult to treat an older, rat sarcoma virus (RAS) and B rapidly accelerated fibrosarcoma (BRAF) wild-type patient. In light of a more detailed characterization of the older population, modernly differentiable between fit, vulnerable, or frail patients on the basis of the comprehensive geriatric assessment, and of the analysis of more recent studies, this review fully collects data from the literature, differentiating the results on functional status patients. MDPI 2022-11-30 /pmc/articles/PMC9739901/ /pubmed/36498683 http://dx.doi.org/10.3390/jcm11237108 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Rosati, Gerardo Montrone, Michele Pacilio, Carmen Colombo, Alfredo Cicero, Giuseppe Paragliola, Fernando Vaia, Angelo Annunziata, Luigi Bilancia, Domenico An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer |
title | An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer |
title_full | An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer |
title_fullStr | An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer |
title_full_unstemmed | An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer |
title_short | An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer |
title_sort | update on the role of anti-egfr in the treatment of older patients with metastatic colorectal cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739901/ https://www.ncbi.nlm.nih.gov/pubmed/36498683 http://dx.doi.org/10.3390/jcm11237108 |
work_keys_str_mv | AT rosatigerardo anupdateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer AT montronemichele anupdateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer AT paciliocarmen anupdateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer AT colomboalfredo anupdateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer AT cicerogiuseppe anupdateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer AT paragliolafernando anupdateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer AT vaiaangelo anupdateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer AT annunziataluigi anupdateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer AT bilanciadomenico anupdateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer AT rosatigerardo updateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer AT montronemichele updateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer AT paciliocarmen updateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer AT colomboalfredo updateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer AT cicerogiuseppe updateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer AT paragliolafernando updateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer AT vaiaangelo updateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer AT annunziataluigi updateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer AT bilanciadomenico updateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer |